Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced thatDeborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held inNew YorkfromSeptember 8-10, 2025.

https://mma.prnewswire.com/media/884786/Armata_Logo.jpg

Armata's presentation is scheduled forWednesday, September 10, from1:30-2:00 PM ET.

To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates forPseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization.

Media Contacts:

At Armata:Pierre Kymeir@armatapharma.com310-594-7035

Investor Relations:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com212-915-2569

https://c212.net/c/img/favicon.png?sn=LA61127&sd=2025-09-04

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302540984.html

SOURCE Armata Pharmaceuticals, Inc.

https://rt.newswire.ca/rt.gif?NewsItemId=LA61127&Transmission_Id=202509040700PR_NEWS_USPR_____LA61127&DateId=20250904

COMTEX_468537892/1005/2025-09-04T07:00:34